Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 May 28;129(7):2653-2654.
doi: 10.1172/JCI128987.

Opioid-galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone

Comment

Opioid-galanin receptor heteromers differentiate the dopaminergic effects of morphine and methadone

Randal A Serafini et al. J Clin Invest. .

Abstract

As the opioid addiction crisis reaches epidemic levels, the identification of opioid analgesics that lack abuse potential may provide a path to safer treatment of chronic pain. Preclinical studies have demonstrated that galanin affects physical dependence and rewarding actions associated with morphine. In the brain and periphery, galanin and opioids signal through their respective GPCRs, GalR1-3 and the μ-opioid receptor (MOR). In this issue of the JCI, Cai and collaborators reveal that heteromers between GalR1 and MOR in the rat ventral tegmental area attenuate the potency of methadone, but not other opioids, in stimulating the dopamine release that produces euphoria. These studies help us understand why some synthetic opioids, such as methadone, do not trigger the release of dopamine in the mesolimbic system but still possess strong analgesic properties.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Comment on

  • Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.
    Cai NS, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, Billing AS, Massey E, Wagner M, Wish ED, Guitart X, Rea W, Lam S, Moreno E, Casadó-Anguera V, Greenblatt AD, Jacobson AE, Rice KC, Casadó V, Newman AH, Winkelman JW, Michaelides M, Weintraub E, Volkow ND, Belcher AM, Ferré S. Cai NS, et al. J Clin Invest. 2019 Mar 26;129(7):2730-2744. doi: 10.1172/JCI126912. J Clin Invest. 2019. PMID: 30913037 Free PMC article.

References

    1. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths — United States, 2013–2017. MMWR Morb Mortal Wkly Rep. 2019;67(5152):1419–1427. - PMC - PubMed
    1. Novick DM, Salsitz EA, Joseph H, Kreek MJ. Methadone medical maintenance: an early 21st-century perspective. J Addict Dis. 2015;34(2-3):226–237. doi: 10.1080/10550887.2015.1059225. - DOI - PubMed
    1. Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS Neurol Disord Drug Targets. 2006;5(2):225–232. doi: 10.2174/187152706776359600. - DOI - PubMed
    1. Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther. 2007;115(2):177–207. doi: 10.1016/j.pharmthera.2007.05.009. - DOI - PubMed
    1. Crawley JN. Biological actions of galanin. Regul Pept. 1995;59(1):1–16. doi: 10.1016/0167-0115(95)00083-N. - DOI - PubMed